<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093469</url>
  </required_header>
  <id_info>
    <org_study_id>II-AF-ATD-Aquaphor</org_study_id>
    <nct_id>NCT01093469</nct_id>
  </id_info>
  <brief_title>Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis</brief_title>
  <official_title>An Investigator Blinded, Randomized, Controlled Study Comparing the Efficacy and Cost-Effectiveness of Aquaphor Healing Ointment, Atopiclair Nonsteroidal Cream (MAS063DP) and EpiCeram Skin Barrier Emulsion in Children With Mild to Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and cost effectiveness of Aquaphor
      Healing Ointment, Atopiclair and EpiCeram as a monotherapy in mild to moderate AD.

      The investigators hypothesize that no statistical difference will exist in the efficacy
      between an over-the-counter moisturizer, Aquaphor Healing Ointment, compared to prescription
      devices Atopiclair and EpiCeram in treating mild to moderate AD. Therefore, Aquaphor will be
      most cost-effective than Atopiclair or EpiCeram.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to compare the efficacy of Aquaphor Healing Ointment, Atopiclair
      Nonsteroidal Cream and EpiCeram Skin Barrier Emulsion in children with mild to moderate
      atopic dermatitis. The secondary objective is to compare the cost-effectiveness of these
      products. A significant difference exists in the cost of these products; therefore, if our
      hypothesis is proved correct - that Aquaphor will be just as efficacious as the more
      expensive counterparts Atopiclair and EpiCeram - this could have a significant impact on the
      overall cost of treating atopic dermatitis.

      This is a single center, investigator blinded, randomized, prospective controlled study of
      subjects with mild to moderate atopic dermatitis. The study is intended to compare the
      efficacy of Aquaphor Healing Ointment, Atopiclair Nonsteroidal Cream and the EpiCeram Skin
      Barrier Emulsion used three times a day in treating mild to moderate atopic dermatitis. All
      subjects will receive active study medication and will return to study center for efficacy
      and safety assessments at Days 7 and 21. Approximately 50 subjects will be enrolled in order
      to obtain 39 completed subjects that will be randomized 1:1:1 (13 to receive Aquaphor, 13 to
      receive Atopiclair and 13 to receive EpiCeram) according to standard randomization tables.
      Efficacy will be measured through Investigator's Global Assessment, BSA involvement,
      Investigator Global Assessment of Improvement, Eczema Area and Severity Index and 100-pt
      Visual Analog Score for pruritis. Subjects will complete a Subject Global Assessment of
      Improvement and a drug diary to monitor for compliance. Cost benefit analysis will be
      calculated as cost in dollars for change in outcome according to EASI, BSA and VAS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment of Improvement</measure>
    <time_frame>Day 21</time_frame>
    <description>This measures the overall response to treatment and quantifies disease on a 6 point scale from &quot;completely clear&quot; to &quot;worsening of disease&quot;.0= Completely clear: except for possible residual hyperpigmentation, 1= Almost clear: very significant clearance (about 90%), 2 = Marked improvement: significant improvement (about 75%), 3= Moderate improvement: intermediate between slight and marked; representing about 50% improvements , 4= Slight improvement: some improvement (about 25%); however, significant disease remaining, 5 = No change from baseline, 6 = Worse</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Aquaphor Healing Ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aquaphor Healing Ointment three times daily to atopic dermatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopiclair Nonsteroidal Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EpiCream Skin Barrier Emulsion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atopiclair Nonsteroidal Cream</intervention_name>
    <arm_group_label>Atopiclair Nonsteroidal Cream</arm_group_label>
    <other_name>MAS063DP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aquaphor Healing Ointment</intervention_name>
    <arm_group_label>Aquaphor Healing Ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EpiCeram</intervention_name>
    <arm_group_label>EpiCream Skin Barrier Emulsion</arm_group_label>
    <other_name>BRC-Cer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female with mild to moderate atopic dermatitis, 2-17 years of age, that agree
             to participate and provide written consent (and assent if applicable)

          -  Have an investigator Global Assessment of mild to moderate atopic dermatitis (IGA
             rating of 2-3 in the Investigator Global Assessment)

          -  Percentage of overall body surface area of involvement (BSA) must be &gt; 1% and may
             include facial and intertriginous skin.

        Exclusion Criteria:

          -  Use within 4 weeks of baseline of systemic anti-inflammatory medication, which may
             influence study outcome, such as systemic corticosteroids.

          -  Application or use within 2 weeks of baseline of topical corticosteroid medications or
             topical anti-inflammatory medication, which may influence study outcome.

          -  Presence of a concurrent medical condition, which is determined by the investigator to
             potentially interfere with study outcomes or patient assessments.

          -  Introduction of any other prescription medication, topical or systemic, for atopic
             dermatitis while participating int he study (oral antihistamines will be allowed, so
             long as they are neither initiated nor discontinued during the course of this study)

          -  Amount of disease involvement that would require &gt;60gm of cream in a 1 week period

          -  Subjects with known allergy or sensitivity to Aquaphor Healing Ointment, Atopiclair or
             EpiCeram or components therein.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Fleischer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences Department of Dermatology</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <results_first_submitted>January 26, 2017</results_first_submitted>
  <results_first_submitted_qc>April 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2017</results_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Wake Forest</keyword>
  <keyword>Dermatology</keyword>
  <keyword>Skin</keyword>
  <keyword>Over-the-counter</keyword>
  <keyword>Moisturizer</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decanoic acid</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
    <mesh_term>Glycyrrhetinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aquaphor Healing Ointment</title>
          <description>Aquaphor Healing Ointment three times daily to atopic dermatitis</description>
        </group>
        <group group_id="P2">
          <title>Atopiclair Nonsteroidal Cream</title>
          <description>Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis</description>
        </group>
        <group group_id="P3">
          <title>EpiCream Skin Barrier Emulsion</title>
          <description>EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aquaphor Healing Ointment</title>
          <description>Aquaphor Healing Ointment three times daily to atopic dermatitis</description>
        </group>
        <group group_id="B2">
          <title>Atopiclair Nonsteroidal Cream</title>
          <description>Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis</description>
        </group>
        <group group_id="B3">
          <title>EpiCream Skin Barrier Emulsion</title>
          <description>EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Investigator Global Assessment of Improvement</title>
        <description>This measures the overall response to treatment and quantifies disease on a 6 point scale from “completely clear” to “worsening of disease”.0= Completely clear: except for possible residual hyperpigmentation, 1= Almost clear: very significant clearance (about 90%), 2 = Marked improvement: significant improvement (about 75%), 3= Moderate improvement: intermediate between slight and marked; representing about 50% improvements , 4= Slight improvement: some improvement (about 25%); however, significant disease remaining, 5 = No change from baseline, 6 = Worse</description>
        <time_frame>Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aquaphor Healing Ointment</title>
            <description>Aquaphor Healing Ointment three times daily to atopic dermatitis</description>
          </group>
          <group group_id="O2">
            <title>Atopiclair Nonsteroidal Cream</title>
            <description>Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis</description>
          </group>
          <group group_id="O3">
            <title>EpiCream Skin Barrier Emulsion</title>
            <description>EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Assessment of Improvement</title>
          <description>This measures the overall response to treatment and quantifies disease on a 6 point scale from “completely clear” to “worsening of disease”.0= Completely clear: except for possible residual hyperpigmentation, 1= Almost clear: very significant clearance (about 90%), 2 = Marked improvement: significant improvement (about 75%), 3= Moderate improvement: intermediate between slight and marked; representing about 50% improvements , 4= Slight improvement: some improvement (about 25%); however, significant disease remaining, 5 = No change from baseline, 6 = Worse</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="1.7"/>
                    <measurement group_id="O2" value="2" spread="2.0"/>
                    <measurement group_id="O3" value="2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aquaphor Healing Ointment</title>
          <description>Aquaphor Healing Ointment three times daily to atopic dermatitis</description>
        </group>
        <group group_id="E2">
          <title>Atopiclair Nonsteroidal Cream</title>
          <description>Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis</description>
        </group>
        <group group_id="E3">
          <title>EpiCream Skin Barrier Emulsion</title>
          <description>EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MRSA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Worsening ATD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Alan Fleischer</name_or_title>
      <organization>Wake Forest</organization>
      <phone>336-716-3775</phone>
      <email>adclark@wakehalth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

